Novo Nordisk Halts AERx Development, But Not Giving Up On All Inhaled Insulin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novo Nordisk is halting development of its Phase III AERx inhaled insulin product after determining it would not offer measurable benefit over currently available pen injection devices, the Danish firm announced Jan. 14